Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury

Xiuli Li, Kan Zhong, Zitao Guo, Dafang Zhong and Xiaoyan Chen
Drug Metabolism and Disposition November 2015, 43 (11) 1751-1759; DOI: https://doi.org/10.1124/dmd.115.064121
Xiuli Li
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kan Zhong
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zitao Guo
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dafang Zhong
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyan Chen
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 43 no. 11 1751-1759
DOI 
https://doi.org/10.1124/dmd.115.064121
PubMed 
26276582

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received March 3, 2015
  • Accepted August 12, 2015
  • Published online October 12, 2015.

Article Versions

  • Earlier version (August 14, 2015 - 05:33).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Xiuli Li,
  2. Kan Zhong,
  3. Zitao Guo,
  4. Dafang Zhong, and
  5. Xiaoyan Chen
  1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
  1. Address correspondence to:
    Xiaoyan Chen, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai, 201203, China. E-mail: xychen{at}simm.ac.cn
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: August 2017 to October 2023

AbstractFullPdf
Aug 201714035
Sep 201753625
Oct 201736046
Nov 2017134939
Dec 201725537
Jan 201843428
Feb 201824229
Mar 201833270
Apr 201824141
May 201833736
Jun 201835423
Jul 2018366360
Aug 2018399261
Sep 20186510098
Oct 2018358562
Nov 201824424
Dec 201834716
Jan 201924820
Feb 2019210120
Mar 201913112
Apr 201944122
May 201914027
Jun 201932124
Jul 201913829
Aug 201923842
Oct 201925125
Nov 2019259122
Dec 201964094
Jan 202013649
Feb 202045077
Mar 2020756163
May 2020541111
Jun 202013135
Jul 2020047187
Aug 20202177
Sep 202075037
Oct 202044527
Nov 202074036
Dec 202034324
Jan 202183329
Feb 202173420
Mar 202121813
Apr 20219239
May 202142248
Jun 202152619
Jul 202143122
Aug 202173022
Sep 202123030
Oct 202161811
Nov 202154710
Dec 20212469
Jan 20222646
Feb 20222266
Mar 20224342
Apr 20225432
May 20223469
Jun 20224165
Jul 202234818
Aug 20222265
Sep 20224745
Oct 20223283
Nov 20223045
Dec 202232410
Jan 20235565
Feb 202329613
Mar 20233435
Apr 202362318
May 20234048
Jun 20235636
Jul 20234381
Aug 20232021
Sep 202341314
Oct 2023100

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 43 (11)
Drug Metabolism and Disposition
Vol. 43, Issue 11
1 Nov 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

TAK-875 Inhibits Hepatobiliary Transporters

Xiuli Li, Kan Zhong, Zitao Guo, Dafang Zhong and Xiaoyan Chen
Drug Metabolism and Disposition November 1, 2015, 43 (11) 1751-1759; DOI: https://doi.org/10.1124/dmd.115.064121

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

TAK-875 Inhibits Hepatobiliary Transporters

Xiuli Li, Kan Zhong, Zitao Guo, Dafang Zhong and Xiaoyan Chen
Drug Metabolism and Disposition November 1, 2015, 43 (11) 1751-1759; DOI: https://doi.org/10.1124/dmd.115.064121
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Functional Characterization of 29 CYP4F2 Variants
  • Exposure-toxicity relation of apatinib
  • ABC phenomenon potentiates anti-HCC efficacy
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics